<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Postheparin plasma hepatic lipase (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) activity has been shown to correlate with features of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in humans </plain></SENT>
<SENT sid="1" pm="."><plain>We examined <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> postheparin plasma enzyme activity, hepatocyte <z:chebi fb="2" ids="33699">mRNA</z:chebi>, and protein mass in the insulin-resistant, <z:chebi fb="15" ids="28757">fructose</z:chebi>-fed Syrian golden hamster, and the response of the insulin-sensitizing peroxisome proliferator-activated receptor-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Male Syrian golden hamsters were treated for 5 weeks with 1) <z:mpath ids='MPATH_458'>normal</z:mpath> diet (DIET group), 2) 60% <z:chebi fb="15" ids="28757">fructose</z:chebi> diet (FRUC group), or 3) 60% <z:chebi fb="15" ids="28757">fructose</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (20 mmol  </plain></SENT>
<SENT sid="3" pm="."><plain>kg(-1)  </plain></SENT>
<SENT sid="4" pm="."><plain>day(-1)) (FRUC+RSG group) </plain></SENT>
<SENT sid="5" pm="."><plain>Hepatocyte <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi>, protein mass, and postheparin plasma <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> activity were increased in FRUC compared with DIET hamsters </plain></SENT>
<SENT sid="6" pm="."><plain>FRUC+RSG hamsters had partial normalization of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> <z:chebi fb="2" ids="33699">mRNA</z:chebi>, mass, and activity </plain></SENT>
<SENT sid="7" pm="."><plain>There was a shift in the size of <z:chebi fb="15" ids="39026">LDL</z:chebi> particles from large to small in FRUC animals and a shift back to large <z:chebi fb="15" ids="39026">LDL</z:chebi> size in FRUC+RSG </plain></SENT>
<SENT sid="8" pm="."><plain>This is the first demonstration that <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> hepatocyte <z:chebi fb="2" ids="33699">mRNA</z:chebi>, mass, and plasma enzymatic activity increase concomitantly with induction of an insulin-resistant state and can be partially normalized by treatment with an insulin sensitizer </plain></SENT>
<SENT sid="9" pm="."><plain>The increase in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> in insulin-resistant states may play an important role in the typical <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> of these conditions, and reduction of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> could explain some of the beneficial effects of <z:chebi fb="0" ids="50864">insulin sensitizers</z:chebi> on the plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> profile </plain></SENT>
</text></document>